MétaCan
Menu
← Back to cohort
Record W2962587806

La trayectoria metodológica de la evaluación de la eficiencia y su futuro

2019· article· es· W2962587806 on OpenAlexaboutno aff
Miguel Ángel Casado Gómez, Javier Soto Álvarez

Bibliographic record

VenuePapeles de economía española/Papeles de economía española · 2019
Typearticle
Languagees
FieldEconomics, Econometrics and Finance
TopicHealth Systems, Economic Evaluations, Quality of Life
Canadian institutionsnot available
Fundersnot available
KeywordsHumanitiesMedicinePhilosophy
DOInot available

Abstract

fetched live from OpenAlex

espanolLas nuevas intervenciones sanitarias tienen que demostrar su eficiencia a traves de los estudios de eficiencia o evaluaciones economicas. En la actualidad, Australia, Canada, Reino Unido, Escocia, Belgica, Holanda, Suecia, Noruega, Finlandia, Portugal y Hungria emplean formalmente el criterio de coste-efectividad para tomar decisiones en politica farmaceutica. El diseno mas empleado para su realizacion son los modelos analiticos de decision, aunque los estudios clinicos, los registros de pacientes, y la historia clinica electronica cada vez se emplean mas. Los analisis coste-efectividad son los mas usados, utilizando los anos de vida ganados y los anos de vida ajustados por calidad e incluyendo los costes sanitarios y, cuando la perspectiva elegida es la sociedad, tambien costes no sanitarios y costes indirectos. Para analizar los resultados se calcula el cociente coste/efectividad (o utilidad) incremental, realizando siempre un analisis de sensibilidad, que puede ser univariante y/o probabilistico. Es necesario mejorar aspectos metodologicos en las evaluaciones economicas para que cada vez sean mas validas y transparentes, asi como definir su papel en los analisis de decision multicriterio, en los estudios con datos de vida real, en la evaluacion de la inmunooncologia y en la medicina personalizada de precision. EnglishNew health interventions have to demonstrate their efficiency through efficiency studies or economic evaluations. Currently, Australia, Canada, the United Kingdom, Scotland, Belgium, the Netherlands, Sweden, Norway, Finland, Portugal and Hungary formally use the cost-effectiveness criteria to make decisions in pharmaceutical policy. The decision analytical models are the most commonly used design, although clinical studies, patient registries, and electronic medical records are increasingly used. The cost-effectiveness analysis are the most used, using the years of life gained and the qualityadjusted life years and including health costs and, when the chosen perspective is society, also non-health costs and indirect costs. To analyze the results, the incremental cost/effectiveness ratio (or cost/utility ratio) is calculated, always carrying out a sensitivity analysis, which can be univariate and/ or probabilistic. It is necessary to improve methodological aspects in economic evaluations so that they become increasingly valid and transparent, as well as defining their role in multi-criteria decision analysis, in studies with real-life data, in the evaluation of immuno-oncology and in personalized precision medicine.

Fetched live from OpenAlex and de-inverted. Abstracts are not stored in this database: the inverted indexes are 8.6 GB of the frame’s 9.3 GB of text, and the host has 13 GB free.

How this classification was reachedexpand

Full frame machine prediction

Teacher imitation

Not calibrated prevalence, not ground truth. Human validation pending. The Gemma side is a direct model label for every work in the frame, read from the title-only record. The Codex side is a classifier learned from the 10,348 direct Codex labels and calibrated to design-weighted sample rates; fields without enough sample support carry no Codex call. Candidate is the union of the two sides; consensus is their intersection. These outputs are machine_predicted_unvalidated and are not human labels.

metaresearch head score (Codex)0.124
metaresearch head score (Gemma)0.222
Version: metacan-v3-hybrid-931329e0061cValidation status: machine_predicted_unvalidated
Candidate categoriesnone
Consensus categoriesnone
DomainCandidate signal: none · Consensus signal: none
Study designCandidate signal: Theoretical or conceptual · Consensus signal: none
GenreCandidate signal: Methods · Consensus signal: Methods
Teacher disagreement score0.124
Threshold uncertainty score0.658

Distilled classifier scores by category (both heads)

CategoryCodexGemma
Metaresearch0.1240.222
Meta-epidemiology (narrow)0.0030.001
Meta-epidemiology (broad)0.0050.005
Bibliometrics0.0080.010
Science and technology studies0.0010.003
Scholarly communication0.0110.006
Open science0.0030.003
Research integrity0.0030.003
Insufficient payload (model declined to judge)0.0080.001

Machine scores (provisional)

The two teacher heads of the student model, read on this work. A score orders the frame for review; it never asserts a category, and the validation status ships verbatim with every row.

Baseline scores from an immature model (maturity gate not passed, 7 training rounds). Scores rank; they never assert a category.

Opus teacher head0.079
GPT teacher head0.402
Teacher spread0.323 · how far apart the two teachers sit on this one work
Validation statusscore_only:v0-immature-baseline · verbatim from the scoring run: score_only means the number may rank works, and no category label ships from it

Classification

machine, unvalidated

Machine predicted; a candidate call from one source (direct Gemma or distilled Codex), not a consensus.

The models applied no category: nothing in the taxonomy fit this work.
Study designTheoretical or conceptual
Domainnot available
GenreMethods

How this classification was reached, model by model and score by score, is at the end of the page under "How this classification was reached".

Quick stats

Citations0
Published2019
Admission routes1
Has abstractyes

Explore more

Same venuePapeles de economía española/Papeles de economía española→Same topicHealth Systems, Economic Evaluations, Quality of Life→French-language works237,207→